{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:05Z","timestamp":1790959265259,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018937","name":"Bavarian Nordic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.ctarc.2020.100165","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T06:53:13Z","timestamp":1578379993000},"page":"100165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-1517","authenticated-orcid":false,"given":"Panagiotis J.","family":"Vlachostergios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1693","authenticated-orcid":false,"given":"Bishoy M.","family":"Faltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9105","authenticated-orcid":false,"given":"Amin H.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abou","family":"Alaiwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2020.100165_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2020.100165_bib0003","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1055-9965.EPI-06-0743","article-title":"Risk of bladder cancer associated with family history of cancer\u00a0: do low-penetrance polymorphisms account for the increase in risk\u00a0?","volume":"16","author":"Murta-Nascimento","year":"2007","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ctarc.2020.100165_bib0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in nordic countries critical revision of the manuscript for important intellectual content","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ctarc.2020.100165_bib0006","unstructured":"http:\/\/www.ncbi.nlm.nih.gov\/clinvar."},{"key":"10.1016\/j.ctarc.2020.100165_bib0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13059-017-1353-5","article-title":"Evaluation of in silico algorithms for use with ACMG\/AMP clinical variant interpretation guidelines","volume":"18","author":"Ghosh","year":"2017","journal-title":"Genome Biol."},{"issue":"10","key":"10.1016\/j.ctarc.2020.100165_bib0008","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","article-title":"BRCA1 and BRCA2 genetic testing\u2014pitfalls and recommendations for managing variants of uncertain clinical significance","volume":"26","author":"Eccles","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2020.100165_bib0009","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrc.2017.82","article-title":"Genome-wide association studies of cancer: current insights and future perspectives","volume":"17","author":"Sud","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100165_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM200007133430213","article-title":"Will genetics revolutionize medicine?","volume":"343","author":"Holtzman","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.juro.2015.02.081","article-title":"Lynch syndrome: a primer for urologists and panel recommendations","volume":"194","author":"Mork M","year":"2015","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MOU.0000000000000340","article-title":"Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance","volume":"27","author":"Pradere","year":"2017","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.ctarc.2020.100165_bib0013","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/modpathol.2016.171","article-title":"Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome","volume":"30","author":"Harper","year":"2017","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.juro.2017.08.002","article-title":"Universal point of care testing for lynch syndrome in patients with upper tract urothelial carcinoma","volume":"199","author":"Metcalfe","year":"2018","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0016","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2020.100165_bib0017","article-title":"Genomic characterization of upper-tract urothelial carcinoma in patients with lynch syndrome","volume":"2018","author":"Donahu","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2020.100165_bib0018","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2012.07.047","article-title":"Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer","volume":"63","author":"Skeldon","year":"2013","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.ctarc.2020.100165_bib0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/BLC-180180","article-title":"Systematic review: an update on the spectrum of urological malignancies in lynch syndrome","volume":"4","author":"Huang","year":"2018","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100165_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MOU.0000000000000639","article-title":"Lynch syndrome and urologic malignancies: a contemporary review","volume":"29","author":"Lim","year":"2019","journal-title":"Curr. Opin. Urol."},{"issue":"2","key":"10.1016\/j.ctarc.2020.100165_bib0021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrurol.2017.190","article-title":"Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition","volume":"15","author":"Siefker-Radtke","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2020.100165_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6349","key":"10.1016\/j.ctarc.2020.100165_bib0023","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.ctarc.2020.100165_bib0024","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100165_bib0025","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"issue":"4S","key":"10.1016\/j.ctarc.2020.100165_bib0026","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1016\/j.juro.2017.02.1499","article-title":"Germline DNA repair single nucleotide polymorphisms in urothelial cancer patients","volume":"197","author":"Vlachostergios","year":"2017","journal-title":"J. Urol."},{"issue":"13 Suppl","key":"10.1016\/j.ctarc.2020.100165_bib0027","article-title":"Germline single nucleotide polymorphisms in DNA repair genes in urothelial cancer patients","volume":"77","author":"Faltas","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100165_bib0028","unstructured":"http:\/\/exac.broadinstitute.org\/."},{"issue":"15Suppl","key":"10.1016\/j.ctarc.2020.100165_bib0029","article-title":"Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B)","volume":"35","author":"Carlo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15Suppl","key":"10.1016\/j.ctarc.2020.100165_bib0030","article-title":"DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC)","volume":"36","author":"Carlo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100165_bib0031","article-title":"Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.","author":"Carlo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15Suppl","key":"10.1016\/j.ctarc.2020.100165_bib0032","article-title":"Germline variants in urothelial carcinoma: analysis of pathogenic and likely pathogenic variants in 645 subjects","volume":"37","author":"Abou Alaiwi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100165_bib0033","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer."},{"key":"10.1016\/j.ctarc.2020.100165_bib0034","unstructured":"https:\/\/www.fda.gov\/drugs\/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients."},{"issue":"3","key":"10.1016\/j.ctarc.2020.100165_bib0035","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.23099","article-title":"Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer","volume":"122","author":"Z\u0142owocka","year":"2008","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ctarc.2020.100165_bib0036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41525-017-0032-5","article-title":"Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas","volume":"2","author":"Madubata","year":"2017","journal-title":"NPJ Genom. Med."},{"issue":"7Suppl","key":"10.1016\/j.ctarc.2020.100165_bib0037","article-title":"Germline alterations in urothelial carcinoma (UC) patients with family history of UC","volume":"37","author":"Nassar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100165_bib0038","article-title":"Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.","author":"Nassar","year":"2019","journal-title":"Genet. Med."},{"issue":"17","key":"10.1016\/j.ctarc.2020.100165_bib0039","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1158\/0008-5472.CAN-09-1091","article-title":"Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer","volume":"69","author":"Stern","year":"2009","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2020.100165_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-170159","article-title":"Bladder cancer genetic susceptibility. A systematic review","volume":"4","author":"de Maturana","year":"2018","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100165_bib0041","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/carcin\/bgq223","article-title":"GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis","volume":"32","author":"Moore","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctarc.2020.100165_bib0042","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/hmg\/ddr619","article-title":"Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer","volume":"21","author":"Tang","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ctarc.2020.100165_bib0043","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/ng.3670","article-title":"Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors","volume":"48","author":"Middlebrooks","year":"2016","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.ctarc.2020.100165_bib0044","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2020.100165_bib0045","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1158\/0008-5472.CAN-14-1531","article-title":"The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease","volume":"74","author":"Fu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100165_bib0046","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1158\/1541-7786.MCR-16-0123","article-title":"Transcription factor KLF5 binds a cyclin E1 polymorphic intronic enhancer to confer increased bladder cancer risk","volume":"14","author":"Pattison","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.ctarc.2020.100165_bib0047","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"7","key":"10.1016\/j.ctarc.2020.100165_bib0048","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/0008-5472.CAN-12-2388","article-title":"Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer","volume":"73","author":"Garcia-Closas","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2020.100165_bib0049","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/cam4.2143","article-title":"Systematic evaluation of cancer\u2010specific genetic risk score for 11 types of cancer in the cancer genome atlas and electronic medical records and genomics cohorts","volume":"8","author":"Shi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2020.100165_bib0050","unstructured":"https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/bladder-cancer-in-adults-screening."},{"key":"10.1016\/j.ctarc.2020.100165_bib0051","unstructured":"https:\/\/www.cancer.gov\/types\/bladder\/hp\/bladder-screening-pdq."},{"key":"10.1016\/j.ctarc.2020.100165_bib0052","unstructured":"https:\/\/www.cancer.org\/cancer\/bladder-cancer\/detection-diagnosis-staging\/detection.html."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0053","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cncr.27692","article-title":"Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial","volume":"119","author":"Vickers","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2020.100165_bib0054","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00264","article-title":"Clinical activity of olaparib in urothelial bladder cancer with DNA damage response gene mutations","author":"Sweis","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2020.100165_bib0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrclinonc.2015.173","article-title":"Population genetic testing for cancer susceptibility: founder mutations to genomes","volume":"13","author":"Foulkes","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15Suppl","key":"10.1016\/j.ctarc.2020.100165_bib0056","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1200\/JCO.2018.36.15_suppl.1511","article-title":"Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB).","volume":"36","author":"Klek","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2020.100165_bib0057","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1200\/JOP.2016.020057","article-title":"Interest and attitudes of patients with advanced cancer with regard to secondary germline findings from tumor genomic profiling","volume":"13","author":"Hamilton","year":"2017","journal-title":"J. Oncol. Pract."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:18:04Z","timestamp":1762841884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220300022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":57,"alternative-id":["S2468294220300022"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100165","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100165"}}